Immix Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securities registered pursuant to Section 12(b)of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 20, 2025, at the 2025 Annual Meeting (the “Annual Meeting”) of the stockholders of Immix Biopharma, Inc. (the “Company,” “we,” “our,” or “us”), stockholders representing 20,092,566 shares of the Company’s capital stock entitled to vote at the Annual Meeting were present in person or by proxy representing 72.1% of the voting shares issued and outstanding on the record date of April 22, 2025, and constituting a quorum to conduct business at the Annual Meeting. The following sets forth the matters that were voted upon by the Company’s stockholders at the Annual Meeting and the voting results for such matters. These matters are described in more detail in the Proxy Statement.
At the Annual Meeting, stockholders approved the following proposals, which are set forth in their entirety below.
| 1. | Proposal 1: The individuals listed below were elected at the Meeting to serve as directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified: |
| For | Withheld | Broker Non-Votes | ||||||||||
| Ilya Rachman | 14,564,106 | 38,284 | 5,490,176 | |||||||||
| Gabriel Morris | 14,346,975 | 255,415 | 5,490,176 | |||||||||
| Jason Hsu | 14,571,192 | 31,198 | 5,490,176 | |||||||||
| Magda Marquet | 14,527,996 | 74,394 | 5,490,176 | |||||||||
| Helen C. Adams | 13,371,024 | 1,231,366 | 5,490,176 | |||||||||
| Carey Ng | 13,600,473 | 1,001,916 | 5,490,177 | |||||||||
| Jane Buchan | 13,594,737 | 1,007,652 | 5,490,177 | |||||||||
| Yekaterina Chudnovsky | 14,561,546 | 40,844 | 5,490,176 | |||||||||
| 2. | Proposal No. 2: To ratify the appointment of Crowe LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025: |
| For | Against | Abstentions | Broker Non-Votes | |||||||||
| 19,946,506 | 47,622 | 98,438 | — | |||||||||
A majority of shares of common stock present in person or represented by proxy at the Annual Meeting were cast for approval of Proposal No. 2, and as such Proposal No. 2 was approved and ratified at the Annual Meeting.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Immix Biopharma, Inc. | |
| Dated: June 23, 2025 | /s/ Ilya Rachman |
| Ilya Rachman | |
| Chief Executive Officer |